Inside BPIQ Portfolios

Biotech investing is not limited by access to information. It is limited by the ability to pick winning stocks and winning portfolio strategies. Even with strong science and data, consistent outperformance is difficult to achieve for any individual investor or investment group.

With an investing background in biotech dating back to the late 1990s, we have seen that deep diligence by even a very experienced biotech pro on individual companies still often leads to disappointing results. Sexy science and exciting pre-clinical and even early-stage clinical results often don’t translate into long-term clinical and commercial success and stock gains. After years of trying to pick winners with our own small team, we started to pay more attention to biopharma-focused hedge funds (“biofunds”). 

Over time, a consistent pattern emerged: companies held across multiple top biotech-focused hedge funds (“biofunds”) tend to outperform. However, since there are a huge number of strategies based on this pattern, the challenge was to turn this pattern into winning portfolio strategies. This became a multi-year process of backtesting hundreds, and more realistically thousands, of portfolio variations across different structures, weightings, and rebalancing approaches of top holdings of biofunds.

These strategies became the foundation for what are now the BPIQ model portfolios, available on the BPIQ Portfolios Page. Over time, they were refined into several structured formats, including 10A, 10B, Top 15, and the Run-up portfolio, along with a broader Top 50 framework that behaves more like XBI but is designed for better performance^FN1.Across multiple backtests and time periods, these portfolios outperform the XBI (biotech) index in the vast majority of backtests performed. 

Backtesting alone, however, is not sufficient validation. For that reason, we moved into real-money implementation. The first portfolio was launched in April 2023, followed by additional strategies in September 2023. These are live accounts with real capital, not simulated environments, and results have remained consistent with the historical findings, continuing to outperform benchmarks over time (See Figure).

From a practical perspective, these portfolios are not intended to function as simple stock-picking tools, and of course, we are not instructing you to do any stock trades without performing your own diligence and consulting with a professional. Our portfolios are better understood as structured systems that can be used by investors in multiple ways, including idea generation, risk filtering, and validation of existing positions. We continuously update our strategies as we continue to test updated variations across our theme of top-holdings of biofunds, as outlined in BPIQ Portfolio FAQs.

There are, of course, limitations. No strategy eliminates risk, and past performance does not guarantee future results. Individual positions can still underperform, and broader market conditions remain a significant factor. The objective is not to give you investment advice or to suggest that we can guarantee future performance. Our goal is to share our portfolios with you to give you valuable information to help you validate your diligence and to give you ideas of biopharma companies that are worthy of your deeper analysis/attention.

---

If you believe you may be an accredited investor and/or qualified purchaser under SEC rules, and would like to receive future updates if we continue exploring a potential private fund structure based on biopharma hedge-fund favorite companies that may become available to outside investors, CLICK HERE to join our interest list.

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 4/20/26 EJV, MD